Trial
NCT02574637
Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Crohn's Disease
Intervention
Brazikumab IV Infusion
Why stopped
Study was terminated for business reasons; not due to safety or efficacy concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-26